Zobrazeno 1 - 10
of 2 854
pro vyhledávání: '"Disease-modifying therapy"'
Autor:
Bassem Yamout, Raed Alroughani, Jihad Inshasi, Samar Farouk, Fatema Abdulla, Namareq Y. Al-Jarki, Abdulla Alasmi, Sarmad Al Fahad, Jaber Alkhabouri, Khalid Al-Saffar, Beatrice Benedetti, Beatriz Canibano, Dirk Deleu, Ali Hassan, Pournamy Sarathchandran, Ahmed Shatila, Mohammad Abouelnaga, Mona Thakre, Miklos Szolics, Amir Boshra
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1321-1335 (2024)
Abstract Cladribine tablets (CladT), like alemtuzumab, acts as an immune reconstitution therapy. However, CladT is administered orally (alemtuzumab is given by infusion) and without the potential for serious side effects that limit the therapeutic us
Externí odkaz:
https://doaj.org/article/a456e8fecb904caa838b18d50372bc33
Autor:
Hyung-Ik Shin
Publikováno v:
Annals of Rehabilitation Medicine, Vol 48, Iss 4, Pp 229-238 (2024)
The impact of disease-modifying therapy ranges from cure to no impact with a wide range of intermediates. In cases where the intermediate group reaches a plateau after the acquisition of some muscle strength, it is necessary to set a functional level
Externí odkaz:
https://doaj.org/article/d8b44cc293fd4d4aa61de64d585de1b2
Autor:
Seyedeh Sadigheh Hamzavi, Rosemina Bahrololoom, Sepideh Saeb, Nahid Heydari Marandi, Marzieh Hosseini, Alimohammad Keshtvarz hesam abadi, Marzieh Jamalidoust
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background For the past three years, the pandemic has had a major effect on global public health, mainly on those with underlying medical conditions, such as people living with Multiple Sclerosis. Vaccination among this group is of great imp
Externí odkaz:
https://doaj.org/article/4ca85b3b60ce471790ed91864595c771
Publikováno v:
Patient Preference and Adherence, Vol Volume 18, Pp 1195-1203 (2024)
Efrat Neter,1 Efrat Esterkin-Hubner,2 Lea Glass-Marmor,2 Anat Wolkowitz,2 Idit Lavi3 ,† Ariel Miller2,4 1Ruppin Academic Center, Emeq Hefer, Israel; 2Multiple Sclerosis Center & Department of Neurology,Carmel Medical Center, Haifa, Israel; 3Departm
Externí odkaz:
https://doaj.org/article/05adf3d54bab40f9a7e319f72e9dd0f1
Autor:
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, Donna Nahal, Celia Oreja-Guevara, Saúl Reyes, Helen Gray, Hashem Salloukh, Gavin Giovannoni
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1015-1038 (2024)
Abstract Cladribine tablets have been granted marketing authorization in Europe and approved by the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple sclerosis (MS). However, people with MS (PwMS) may be more familiar
Externí odkaz:
https://doaj.org/article/ff669389683b41fc8e84651bf0ac2db2
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background To date, no disease modifying therapies are available for Parkinson’s disease (PD). Since PD is the second most prevalent neurodegenerative disorder, there is a high demand for such therapies. Both environmental and genetic risk
Externí odkaz:
https://doaj.org/article/83c29f7a88ce474dac5b13ca0342c630
Publikováno v:
罕见病研究, Vol 3, Iss 2, Pp 246-251 (2024)
Neuromyelitis optic spectrum disorders (NMOSD) is a serious inflammatory demyelinating disease. Clinical treatment of NMOSD mainly involves acute phase treatment and remission phase prevention treatment. Disease-modifying therapy (DMT) in remission p
Externí odkaz:
https://doaj.org/article/b3455942499c40d6a0e9f891af29608a
Autor:
Jerome de Seze, Dominique Dive, Xavier Ayrignac, Giovanni Castelnovo, Marianne Payet, Amel Rayah, Claudio Gobbi, Patrick Vermersch, Chiara Zecca
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 519-533 (2024)
Abstract The number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisati
Externí odkaz:
https://doaj.org/article/da10c1e30c4d425eada5c230eab87fc9
Autor:
Simón Cárdenas-Robledo, Laura Estefanía Arenas-Vargas, Rubén Darío Arenas, Jorge Mario Gaspar-Toro, Ángela María Muñoz-Rosero, Aranza Helena Tafur-Borrero, Daniel Stiven Marín-Medina, Hernan Andrés Acosta-Fajardo, Claudia Guío-Sánchez, Lorena López-Reyes
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Effective interventions for Multiple Sclerosis require timely treatment optimization which usually involves switching disease modifying therapies. The patterns of prescription and the reasons for changing treatment in people with
Externí odkaz:
https://doaj.org/article/224e7530d5a14664a311fb41827a1241
Autor:
Esther Ganelin‐Cohen, Chen Buxbaum, Noam Bosak, Shani Sobol, Adi Vaknin‐Dembinsky, Mark A Hellmann, Adi Wilf‐Yarkoni, Keren Regev, Elizaveta Pustovoyt, Alla Shifrin, Yair Wexler, Ayal Rozenberg
Publikováno v:
Brain and Behavior, Vol 14, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Examining the safety of theBNT162b2 mRNA vaccine in multiple sclerosis (MS) patients remains inconclusive, particularly regarding the potential for disease exacerbations. This study aims to assess the effects of BNT162b2 COVID
Externí odkaz:
https://doaj.org/article/83f6312cb48b48198f138f5ff81dad63